MapLight Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
MapLight Therapeutics sold 13,181,055 shares and pre-funded warrants (strike $0.0001) to institutional investors at $11.38/share and $11.3799/warrant on August 13, 2026, raising $150M gross. The offering includes standard registration rights, warrant terms, and a 4.99% beneficial ownership cap. Proceeds fund ML-007C-MA clinical trials (Phase 3 ZEPHYR-2 in schizophrenia, Phase 2 VISTA in Alzheimer's psychosis) through 2028.
Why this rating
Private placement is routine for clinical-stage biotech. $150M is material to cash runway but represents standard dilutive financing, not M&A or transformational event.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.